CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.
The court cited previous US Supreme Court rulings, including Mayo vs. Prometheus, in determining that certain claims of Illumina's patents were invalid.
The lawsuit comes a few days after a jury awarded Bio-Rad Laboratories $23.9 million in damages in a patent infringement suit against 10x Genomics.
The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.
A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.
Vox writes that lab mishaps involving pathogens are quite common.
In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.